Business
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024
About this update from Cytomed Therapeutics Limited
[{"type":"image","alt":"CYTOMED THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"CYTOMED THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":139,"url":"https://media.zenfs.com/en/globenewswire.com/a5ea200fbc7d9222864b186d49fef81e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kZfTE6ya73voiEtLPclhmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a5ea200fbc7d9222864b186d49fef81e","width":300,"height":139}},"lazy":false},{"type":"text","content":"SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024 financial results and provided clinical and corporate updates.","length":567,"tagName":"p"},{"type":"text","content":"We intend to be among the early pioneers of cellular immunotherapy treatment modalities to serve the ASEAN region and North Asia with a population of more than two billion. Capitalizing on Asia’s low-cost infrastructure and talents, we make affordable GMP-grade immune cells to be infused into no-option patients, aiming to explore their potential applications in addressing cancers or autoimmune diseases. This operation continued to grow in 2024 especially with rising interest from doctors and researchers in donor-derived off-the-shelf allogeneic gamma delta T cells, a rare subset of cancer-killing T cells.","length":612,"tagName":"p"},{"type":"text","content":"Topline income amounted to US$624,771 in 2024 compared to US$588,423 in 2023. Cash and bank balances amounted to US$3.64 million as of December 31, 2024. We did not need to raise new money in 2024 despite using internal resources to acquire a new premise for expanded operations and invest in a new licensed business of cord blood banking which will be strategically transformed into our wellness and regenerative arm targeting auto-immune diseases.","length":449,"tagName":"p"},{"type":"text","content":"Financial Results for the ...